Efficacy and Safety of Mazdutide in Managing Overweight and Obesity Among Non-Diabetic Adults: A Meta-Analysis of Randomised Controlled Trials.

IF 5.7 2区医学 Q1 ENDOCRINOLOGY & METABOLISM

Diabetes, Obesity & Metabolism Pub Date : 2026-06-01 Epub Date: 2026-03-10 DOI:10.1111/dom.70643

Muhammad Hassan Azam, Muhammad Hussain Azam, Khair-Un-Nisa Azam, Muhammad Ahmed Azam, Muhammad Khalid Afridi, Saad Ahmed Waqas, Muhammad Sharjeel Abbas, Hasibullah Aminpoor, Raheel Ahmed

{"title":"Efficacy and Safety of Mazdutide in Managing Overweight and Obesity Among Non-Diabetic Adults: A Meta-Analysis of Randomised Controlled Trials.","authors":"Muhammad Hassan Azam, Muhammad Hussain Azam, Khair-Un-Nisa Azam, Muhammad Ahmed Azam, Muhammad Khalid Afridi, Saad Ahmed Waqas, Muhammad Sharjeel Abbas, Hasibullah Aminpoor, Raheel Ahmed","doi":"10.1111/dom.70643","DOIUrl":null,"url":null,"abstract":"Background: Mazdutide, a dual GLP-1 and glucagon receptor agonist, shows promise for weight loss and glycaemic control. This study evaluates its efficacy in non-diabetic patients with obesity.Methodology: A search of Cochrane Library, PubMed, Google Scholar and clinicaltrials.gov identified randomised controlled trials (RCTs) of mazdutide in adults (≥ 18 years) with obesity. Meta-analysis was performed using RevMan 5.4 with random-effect models.Results: Five RCTs were included. Mazdutide significantly reduced percentage body weight (MD = -12.42%, 95% CI: -16.15% to -8.68%), absolute body weight (MD = -9.76 kg, 95% CI: -13.15 to -6.37 kg) and waist circumference (MD = -7.98 cm, 95% CI: -10.24 to -5.72 cm). Systolic blood pressure (MD = -7.68 mmHg), total cholesterol (MD = -0.57 mmol/L) and LDL (MD = -0.37 mmol/L) also decreased. Adverse events were slightly increased (RR = 1.12). Dose-wise meta-regression showed significant effects (β = -0.99, 95% CI: -1.81 to -0.16; p = 0.0187).Conclusion: Mazdutide effectively reduces weight, waist circumference and blood pressure but may cause mild to moderate adverse events. Findings are limited by the small number of RCTs.","PeriodicalId":158,"journal":{"name":"Diabetes, Obesity & Metabolism","volume":" ","pages":"4464-4473"},"PeriodicalIF":5.7000,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Diabetes, Obesity & Metabolism","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/dom.70643","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/3/10 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Mazdutide, a dual GLP-1 and glucagon receptor agonist, shows promise for weight loss and glycaemic control. This study evaluates its efficacy in non-diabetic patients with obesity.

Methodology: A search of Cochrane Library, PubMed, Google Scholar and clinicaltrials.gov identified randomised controlled trials (RCTs) of mazdutide in adults (≥ 18 years) with obesity. Meta-analysis was performed using RevMan 5.4 with random-effect models.

Results: Five RCTs were included. Mazdutide significantly reduced percentage body weight (MD = -12.42%, 95% CI: -16.15% to -8.68%), absolute body weight (MD = -9.76 kg, 95% CI: -13.15 to -6.37 kg) and waist circumference (MD = -7.98 cm, 95% CI: -10.24 to -5.72 cm). Systolic blood pressure (MD = -7.68 mmHg), total cholesterol (MD = -0.57 mmol/L) and LDL (MD = -0.37 mmol/L) also decreased. Adverse events were slightly increased (RR = 1.12). Dose-wise meta-regression showed significant effects (β = -0.99, 95% CI: -1.81 to -0.16; p = 0.0187).

Conclusion: Mazdutide effectively reduces weight, waist circumference and blood pressure but may cause mild to moderate adverse events. Findings are limited by the small number of RCTs.

查看原文本刊更多论文

马都肽治疗非糖尿病成人超重和肥胖的有效性和安全性：一项随机对照试验的荟萃分析。

背景：Mazdutide是一种双重GLP-1和胰高血糖素受体激动剂，具有减轻体重和控制血糖的前景。本研究评价其对非糖尿病合并肥胖患者的疗效。方法：检索Cochrane Library、PubMed、b谷歌Scholar和clinicaltrials.gov，确定了mazdutide在成人（≥18岁）肥胖患者中的随机对照试验（RCTs）。meta分析采用RevMan 5.4，采用随机效应模型。结果：共纳入5项rct。Mazdutide显著降低了体重百分比（MD = -12.42%, 95% CI: -16.15%至-8.68%）、绝对体重（MD = -9.76 kg, 95% CI: -13.15至-6.37 kg）和腰围（MD = -7.98 cm, 95% CI: -10.24至-5.72 cm）。收缩压（MD = -7.68 mmHg）、总胆固醇（MD = -0.57 mmol/L）和低密度脂蛋白（MD = -0.37 mmol/L）也有所下降。不良事件略有增加（RR = 1.12）。剂量方向的meta回归显示显著影响（β = -0.99, 95% CI: -1.81 ~ -0.16; p = 0.0187）。结论：马都肽能有效地降低体重、腰围和血压，但可能引起轻中度不良反应。由于随机对照试验的数量较少，研究结果受到限制。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Diabetes, Obesity & Metabolism 医学-内分泌学与代谢

CiteScore

10.90

自引率

6.90%

发文量

319

审稿时长

3-8 weeks

期刊介绍： Diabetes, Obesity and Metabolism is primarily a journal of clinical and experimental pharmacology and therapeutics covering the interrelated areas of diabetes, obesity and metabolism. The journal prioritises high-quality original research that reports on the effects of new or existing therapies, including dietary, exercise and lifestyle (non-pharmacological) interventions, in any aspect of metabolic and endocrine disease, either in humans or animal and cellular systems. ‘Metabolism’ may relate to lipids, bone and drug metabolism, or broader aspects of endocrine dysfunction. Preclinical pharmacology, pharmacokinetic studies, meta-analyses and those addressing drug safety and tolerability are also highly suitable for publication in this journal. Original research may be published as a main paper or as a research letter.